查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790317

照护现场药物滥用检测市场规模、份额和趋势分析报告：按产品、样本类型、技术、最终用途、地区和细分市场进行预测，2025 年至 2033 年

Point Of Care Drug Of Abuse Testing Market Size, Share & Trends Analysis Report By Product (Immunoassay Test Strips And Cassettes, Oral Fluid Testing Kits), By Sample Type, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 136 Pages | 商品交期: 2-10个工作天内

价格

照护现场（POC）药物滥用（DOA）检测市场概览

2024 年全球 POC 药物滥用检测市场规模估计为 10.8 亿美元，预计到 2033 年将达到 24.5 亿美元，2025 年至 2033 年期间的复合年增长率为 9.62%。 POC 测试包括尿液、唾液、呼吸和汗液试剂套件，可在样本采集时快速提供结果，无需复杂的实验室基础设施。

这些工具越来越多地被应用于临床环境、路边执法、学校甚至家庭，成为全球公共卫生和安全策略的重要组成部分。技术进步显着提高了 POC DOA 检测设备的准确性、速度和易用性。基于免疫测量测定的测试条、可携式分析仪和数位阅读器的开发，可以用最少的样品处理快速获得结果。人工智慧和机器学习开始被整合到一些测试平台中，以帮助解释结果并减少操作员错误。口腔液和汗液测试等非侵入性采样方法正在提高使用者的依从性和隐私性。此外，新设备现在支援多面板药物测试，可以同时检测多种物质，包括鸦片类药物、大麻、古柯碱、安非他命和苯二氮平类药物。这种技术创新在急诊、警察局和復健中心等需要快速决策的环境中至关重要。诊断技术的小型化和连接性的改善（包括智慧型手机整合和蓝牙资料登录）使得这些工具更易于使用和用户友好，从而刺激了专业市场和消费者市场的采用。

政府法规和职场安全措施是 POC DOA 检测市场的主要驱动力。在美国等国家，联邦法令要求对交通运输、航空和医疗保健等安全关键产业进行药物筛检。这导致了即时检验 (POC)检测套组可提供快速筛检，除非发现阳性结果，否则无需实验室确认。路边药物检测计划，特别是在大麻使用合法化的司法管辖区，也在推动对准确和便携式 POC 设备的需求。此外，学校毒品预防计划和军事招募流程越来越多地采用快速筛检方法，以儘早阻止和发现药物使用。在欧洲和亚洲部分地区，职场安全法和反兴奋剂措施正在不断发展，支持更广泛的实施。这些框架不仅促进公共，而且还对可靠、经济高效且易于使用的测试解决方案产生了稳定的需求，这些解决方案可以部署在各种分散式环境中。

随着人们对隐私、便利性和自我监测的需求日益增长，居家 DOA 检测的需求显着增加。这些套件让人们在私密环境中使用唾液、尿液或毛髮样本对自己或他人进行检测。随着消费者和医疗保健提供者寻求远端监测自身健康状况的方法，COVID-19 疫情进一步加速了自我检测模式的普及。远距远端医疗服务也为接受成瘾治疗和疼痛管理的患者提供了这些套件，从而增强了护理的连续性。

目录

第 1 章。照护现场药物滥用检测市场：调查方法与范围

第 2 章照护现场药物滥用检测市场：执行摘要

  • 市场概述
  • 产品与应用简介
  • 测试类型简介
  • 竞争格局简介

第三章照护现场药物滥用检测市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素分析
    • 药物滥用率上升
    • 检测设备的技术进步
    • 对分布式测验的兴趣日益浓厚
  • 市场限制因素分析
    • 假阳性/假阴性的风险
    • 监管和报销挑战
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章照护现场药物滥用检测市场：产品、预测与趋势分析

  • 照护现场药物滥用检测市场：产品差异分析
  • 免疫检测条和测试盒
  • 口腔液体检测套组
  • 呼吸分析仪
  • 尿液收集杯
  • 数位/可携式分析仪

第五章照护现场药物滥用检测市场：按样本类型进行的估算和趋势分析

  • 照护现场药物滥用检测市场：样本类型变异分析
  • 尿
  • 唾液（口腔液体）
  • 呼吸
  • 血
  • 汗水/头髮

第六章：照护现场药物滥用检测市场（按技术、估算和趋势分析）

  • 照护现场药物滥用检测市场：技术变革分析
  • 横向流动化验（LFA）
  • 层析法免疫检测
  • 酵素免疫分析法（ELISA）
  • 质谱法（可携式或混合式 POC 装置）

第七章照护现场药物滥用检测市场：按最终用途的估计和趋势分析

  • 照护现场药物滥用检测市场：最终用途变异分析
  • 医院和急诊部
  • 职场和职业健康中心
  • 居家医疗和远端用户
  • 其他的

第八章照护现场药物滥用检测市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第九章 竞争态势

  • 公司分类
  • 战略地图
    • 新产品发布
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市场占有率分析（2024年）
  • 公司热图分析
  • 公司简介
    • ABBOTT
    • QUEST DIAGNOSTICS
    • THERMO FISHER SCIENTIFIC
    • ORASURE TECHNOLOGIES
    • SIEMENS HEALTHINEERS
    • F. HOFFMANN-LA ROCHE LTD.
    • Dragerwerk AG & Co. KGaA
    • LABCORP（LABORATORY CORPORATION OF AMERICA HOLDINGS）
    • PREMIER BIOTECH, INC.
Product Code: GVR-4-68040-662-7

Point Of Care Drug Of Abuse Testing Market Summary

The global point of care drug of abuse testing market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 2.45 billion by 2033, growing at a CAGR of 9.62% from 2025 to 2033, due to increasing substance misuse worldwide and the urgent need for rapid, decentralized drug testing solutions. POC testing, which includes urine, saliva, breath, and sweat-based kits, provides rapid results at the site of sample collection, eliminating the need for complex lab infrastructure.

These tools are increasingly being adopted in clinical settings, roadside enforcement, schools, and even at home, making them a key component in public health and safety strategies globally. Technological advancements are significantly enhancing the accuracy, speed, and usability of POC DOA testing devices. The development of immunoassay-based test strips, portable analyzers, and digital readers enables fast results with minimal sample handling. AI and machine learning are beginning to integrate into some testing platforms, assisting in result interpretation and reducing operator error. Non-invasive sampling methods, such as oral fluid and sweat-based testing, are improving user compliance and privacy. In addition, newer devices now support multi-panel drug testing, enabling simultaneous detection of multiple substances such as opioids, cannabis, cocaine, amphetamines, and benzodiazepines. These innovations are crucial in settings where quick decision-making is essential-such as emergency departments, law enforcement operations, and rehabilitation centers. The miniaturization of diagnostic technology and improved connectivity features, including smartphone integration and Bluetooth-enabled data logging, are making these tools more accessible and user-friendly, driving adoption in both professional and consumer markets.

Government regulations and workplace safety initiatives are key drivers in the expansion of the POC DOA testing market. In countries such as the U.S., federal mandates require drug screening for safety-sensitive industries such as transportation, aviation, and healthcare. This has led to widespread use of on-site testing kits that provide rapid screening without needing laboratory confirmation unless a positive result arises. Roadside drug testing programs, particularly in jurisdictions with legalized cannabis use, are also boosting demand for accurate and mobile POC devices. Moreover, school drug prevention programs and military recruitment processes increasingly incorporate quick screening methods to deter and identify drug use early. In Europe and parts of Asia, evolving workplace safety laws and anti-doping initiatives are supporting broader implementation. These frameworks not only promote public safety but also create a steady demand for reliable, cost-effective, and easy-to-use testing solutions that can be deployed in a range of decentralized environments.

The growing demand for privacy, convenience, and self-monitoring has led to a significant rise in at-home DOA testing. These kits allow individuals to test themselves or others in private settings using saliva, urine, or hair samples. The COVID-19 pandemic further accelerated the adoption of self-testing models, as consumers and healthcare providers looked for ways to monitor health remotely. Telehealth services have incorporated these kits for patients undergoing addiction treatment or pain management, enhancing continuity of care.

Global Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care drug of abuse testing market based on product, technology, sample type, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay Test Strips and Cassettes
  • Oral Fluid Testing Kits
  • Breath Analyzers
  • Urine Collection Cups
  • Digital/Portable Analyzers
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Lateral Flow Assay (LFA)
  • Chromatographic Immunoassays
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Mass Spectrometry (portable or hybrid POC units)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Emergency Departments
  • Workplace & Occupational Health Center
  • Home Care & Remote Users
  • Others
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Urine
  • Saliva (Oral Fluid)
  • Breath
  • Blood
  • Sweat/Hair
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Point of Care Drug of Abuse (DOA) Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. Test Type segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Point of Care Drug of Abuse (DOA) Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Application Snapshot
  • 2.3. Test Type Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising Substance Abuse Rates
    • 3.4.2. Technological Advancements in Testing Devices
    • 3.4.3. Growing Preference for Decentralized Testing
  • 3.5. Market Restraint Analysis
    • 3.5.1. Risk of False Positives/Negatives
    • 3.5.2. Regulatory and Reimbursement Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

  • 4.1. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
  • 4.2. Immunoassay Test Strips and Cassettes
  • 4.3. Oral Fluid Testing Kits
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Breath Analyzers
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Urine Collection Cups
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Digital/Portable Analyzers
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

  • 5.1. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Movement Analysis
  • 5.2. Urine
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Saliva (Oral Fluid)
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Breath
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Blood
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Sweat/Hair
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

  • 6.1. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
  • 6.2. Lateral Flow Assay (LFA)
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Chromatographic Immunoassays
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Mass Spectrometry (portable or hybrid POC units)
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

  • 7.1. Point of Care Drug of Abuse (DOA) Testing Market: End Use Movement Analysis
  • 7.2. Hospitals & Emergency Departments
    • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Workplace & Occupational Health Center
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Home Care & Remote Users
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point of Care Drug of Abuse (DOA) Testing Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Point of Care Drug of Abuse (DOA) Testing Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. Germnay
      • 8.3.3.1. Germany Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. Spain
      • 8.3.4.1. Spain Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. France
      • 8.3.5.1. France Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Italy Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. Australia
      • 8.4.7.1. Australia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. NEW PRODUCT LAUNCH
    • 9.2.2. PARTNERSHIPS
    • 9.2.3. ACQUISITION
    • 9.2.4. COLLABORATION
    • 9.2.5. FUNDING
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. ABBOTT
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. QUEST DIAGNOSTICS
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. THERMO FISHER SCIENTIFIC
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. ORASURE TECHNOLOGIES
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. SIEMENS HEALTHINEERS
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. HOFFMANN-LA ROCHE LTD.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Dragerwerk AG & Co. KGaA
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. LABCORP (LABORATORY CORPORATION OF AMERICA HOLDINGS)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. PREMIER BIOTECH, INC.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Point of Care Drug of Abuse (DOA) Testing Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 5 Global Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 6 Global Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 Global Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Point of Care Drug of Abuse (DOA) Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 9 North America Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 10 North America Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 11 North America Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 12 North America Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Point of Care Drug of Abuse (DOA) Testing Market, by Product, 2021 - 2033 (USD Million)
  • Table 19 Canada Point of Care Drug of Abuse (DOA) Testing Market, by Technology, 2021 - 2033 (USD Million)
  • Table 20 Canada Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 23 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 Europe Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Europe Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 31 UK Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 32 UK Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 UK Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 36 Germany Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 37 Germany Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 38 France Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 39 France Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 France Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 France Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 44 Italy Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Italy Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 48 Spain Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 49 Spain Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 51 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 52 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 53 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 55 Norway Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 Norway Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 Norway Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 60 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 69 Japan Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Japan Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 China Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 72 China Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 73 China Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 74 China Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 India Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 76 India Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 77 India Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 78 India Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 81 Australia Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 82 Australia Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 83 Thailand Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 84 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 South Korea Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 88 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 89 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 90 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 98 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 99 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 102 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 103 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 104 MEA Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 105 MEA Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 106 MEA Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 107 MEA Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 108 MEA Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 111 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 112 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 119 UAE Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 120 UAE Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD)
  • Table 122 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global point of care drug of abuse (DOA) testing market - Key market driver analysis
  • Fig. 7 Global point of care drug of abuse (DOA) testing market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global point of care drug of abuse (DOA) testing market - Porter's analysis
  • Fig. 10 Global point of care drug of abuse (DOA) testing market - PESTEL analysis
  • Fig. 11 Global point of care drug of abuse (DOA) testing market product outlook key takeaways
  • Fig. 12 Global point of care drug of abuse (DOA) testing market: Product movement analysis
  • Fig. 13 Immunoassay Test Strips and Cassettes
  • Fig. 14 Oral Fluid Testing Kits market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Breath Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Urine Collection Cups market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Digital/Portable Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Global point of care drug of abuse (DOA) testing market sample type outlook key takeaways
  • Fig. 19 Global point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 20 Urine market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Saliva (Oral Fluid) market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Breath market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Blood market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Sweat/Hair market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Global point of care drug of abuse (DOA) testing market technology outlook key takeaways
  • Fig. 26 Global point of care drug of abuse (DOA) testing market: technology movement analysis
  • Fig. 27 Lateral Flow Assay (LFA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Chromatographic Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Enzyme-Linked Immunosorbent Assay (ELISA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Mass Spectrometry (portable or hybrid POC units) market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Global point of care drug of abuse (DOA) testing market end use outlook key takeaways
  • Fig. 32 Global point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 33 Urine market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Global point of care drug of abuse (DOA) testing market: Regional movement analysis
  • Fig. 36 North America point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 41 UK point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 43 France point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 51 China point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 52 India point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 53 South Korea point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 64 Strategy framework